Abstract
Nearly one-third of death worldwide can be attributed to cardiovascular disease (CVD) and 24.8% of all death in India is attributed to CVD. Atherosclerosis is the basis for the majority of CVD and it occurs commonly due to hypercholesterolemia and hypertriglyceridemia. With the introduction of statin, the incidence of CVD has decreased by an average annual-percentage-change (APC) of 3.9%. Therefore, drug therapy for dyslipidemia, lifestyle, and dietary modification are the keystones for the reduction of CVD-related deaths. Statins besides having the hypolipidaemic property have multiple pleiotropic effects. Moreover, the regulation of lipid carrying mechanism have been studied in-depth nowadays and this led to the development of newer drugs like ezetimibe, mipomersen, lomitapide, alirocumab (PCSK-9 inhibitor), and avasimibe. The majority of newer drugs are helpful in controlling lipid levels in various genetic-primary hyperlipoproteinemia conditions. This chapter will review the role of various lipoproteins in lipid transport, drugs available to treat hyperlipidemia, and recent clinical guidelines for dyslipidemia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Aiman U, Najmi A, Khan RA (2014) Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother 5(3):181–185
Ast M, Frishman WH (1990) Bile acid sequestrants. J Clin Pharmacol 30(2):99–106
Boden WE, Sidhu MS, Toth PP (2014) The therapeutic role of niacin in dyslipidemia management. J Cardiovasc Pharmacol Ther 19(2):141–158
Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA (2016) Statins in stroke prevention: present and future. Curr Pharm Des 22(30):4638–4644
Dixon DL, Pamulapati LG, Bucheit JD, Sisson EM, Smith SR, Kim CJ et al (2019) Recent updates on the use of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease. Curr Atheroscler Rep 21(5):16
Do RQ, Vogel RA, Schwartz GG (2013) PCSK9 inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep 15(3):345
Fuccella LM, Goldaniga G, Lovisolo P, Maggi E, Musatti L, Mandelli V et al (1980) Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther 28(6):790–795
Golomb BA, Evans MA (2008) Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8(6):373–418
Hammersley D, Signy M (2017) Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther Adv Chronic Dis 8(1):4–11
Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M (2016) Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 16(11):CD009753
Kavalipati N, Shah J, Ramakrishan A, Vasnawala H (2015) Pleiotropic effects of statins. Indian J Endocrinol Metab 19(5):554–562
Li N, Li Q, Tian X-Q, Qian H-Y, Yang Y-J (2014) Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs 14(5):367–376
Liao JK, Laufs U (2005) Pleiotropic effects OF statins. Annu Rev Pharmacol Toxicol 45:89–118
McKenney J (2003) Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm 60(10):995–1005
Miller DB, Spence JD (1998) Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34(2):155–162
Patel RS, Scopelliti EM, Olugbile O (2018) The role of PCSK9 inhibitors in the treatment of hypercholesterolemia. Ann Pharmacother 52(10):1000–1018
Perry CM (2013) Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs 13(4):285–296
Phan BAP, Dayspring TD, Toth PP (2012) Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 8:415–427
Reeskamp LF, Kastelein JJP, Moriarty PM, Duell PB, Catapano AL, Santos RD et al (2019) Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 280:109–117
Roglans N, Verd JC, Peris C, Alegret M, Vázquez M, Adzet T et al (2002) High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 37(5):445–454
Sperlongano S, Gragnano F, Natale F, D’Erasmo L, Concilio C, Cesaro A et al (2018) Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. J Cardiovasc Med (Hagerstown) 19(3):83–90
Staels B, Handelsman Y, Fonseca V (2010) Bile acid Sequestrants for lipid and glucose control. Curr Diab Rep 10(1):70–77
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Lakshmanan, M. (2021). Drugs Used in Dyslipidemia. In: Paul, A., Anandabaskar, N., Mathaiyan, J., Raj, G.M. (eds) Introduction to Basics of Pharmacology and Toxicology. Springer, Singapore. https://doi.org/10.1007/978-981-33-6009-9_31
Download citation
DOI: https://doi.org/10.1007/978-981-33-6009-9_31
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-33-6008-2
Online ISBN: 978-981-33-6009-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)